Emerging Function and Clinical Values of Exosomal MicroRNAs in Cancer

Man Wang, Fei Yu, Han Ding, Yu Wang, Peifeng Li, and Kun Wang

Exosomes are a subset of membrane-bound extracellular vesicles with diameters ranging from 30 to 100 nm. Exosomes enclose a variety of molecules, such as lipids, proteins, and non-coding RNAs. In the past decades, microRNAs (miRNAs) have attracted great attention in cancer research, as they play an important role in the occurrence and development of cancer. Increasing evidence indicates that tumor cells communicate with not only other tumor cells but also cells present in the tumor microenvironment via secretion and transfer of exosomal miRNAs. More importantly, exosomal miRNAs are found to serve as signaling molecules to regulate tumor growth, angiogenesis, metastasis, sensitivity to chemotherapy, and immune evasion. Deregulated expression of exosomal miRNAs is an early event in carcinogenesis and may reflect the malignant characteristics of cancer. Owing to the wide existence and high stability of exosomal miRNAs in body fluids, they may represent a novel class of non-invasive biomarkers for cancer. In this review, we highlight the recent advances on the functional role of exosomal miRNAs in cancer pathogenesis. We also discuss the potential clinical utility of exosome-shuttled miRNAs as biomarkers for the diagnosis and treatment of cancer.

Exosomes are 30- to 100-nm extracellular vesicles of endosomal origin, comprising a lipid bilayer and a great variety of bioactive molecules, such as nucleic acids, lipids, and proteins. Exosomes are released from all cell types, including epithelial cells, immune cells, and tumor cells. Notably, tumor cells secrete excessive amounts of exosomes compared with normal proliferating cells. Exosomes form within intracellular multivesicular bodies (MVBs), and they are secreted upon fusion of MVBs with the plasma membrane. Exosomes can be detected in almost all body fluids, including blood, urine, and saliva.

Exosomes are critical vehicles for intercellular communication. Thus, they have multiple physiological roles, such as maintenance of cellular homeostasis through the release of intracellular harmful components and activation of immune responses through the delivery of antigens or activating ligands. Emerging evidence demonstrates the crucial role of exosomes in tumor development. Exosomes can be trafficked between tumor cells or between tumor cells and the surrounding microenvironment. Cancer-associated exosomes can promote tumor survival and growth. They contribute to the establishment of a tumor-promoting niche by inducing angiogenesis, remodeling the extracellular matrix, and impairing the function of immune cells. Additionally, exosomes can transmit drug-resistance characteristics among tumor cells.

MicroRNAs (miRNAs) are the most extensively studied class of short non-coding RNAs (ncRNAs). miRNAs regulate the expression of target genes at the post-transcriptional level, primarily via binding to fully or partially complementary sites within the 3’ UTR of target miRNAs. miRNAs are involved in a variety of cellular processes, including cell proliferation, differentiation, and death. Notably, miRNAs have been found to play an important role in the onset and progression of cancer, such as tumor growth, invasion, and metastasis. Therefore, miRNAs may be promising biomarkers for cancer diagnosis and prognosis. miRNAs are critical exosomal constituents, and exosomal miRNAs are confirmed to participate in the occurrence and development of cancer. miRNA-containing exosomes can be shed from parental cells into the circulation, demonstrating that exosomal miRNAs may serve as ideal non-invasive biomarkers for cancer. In this review, we summarize the current knowledge on the role of exosomal miRNAs in carcinogenesis and cancer progression. We also discuss the potential applications of exosomal miRNAs as cancer biomarkers in clinical practice.

Exosome Biogenesis

Exosomes are generated by both normal and pathological cells and are found in all body fluids. Exosomes originate from the endosomal compartment. The biogenesis of exosomes involves two steps. First, the internalization of the cell membrane leads to the formation of early endosomes (Figure 1). Multiple intraluminal vesicles (ILVs) are then formed by the inward invagination of endosomal membranes, resulting in the formation of MVBs. During this process, cytosolic constituents, including nucleic acids, proteins, and lipids, can be sorted into ILVs. Upon fusion of MVBs with the plasma membrane, ILVs are released as exosomes into the extracellular milieu.

Some factors have been found to be involved in exosome biogenesis. The endosomal sorting complexes required for transport (ESCRTs)

https://doi.org/10.1016/j.omtn.2019.04.027.

Correspondence: Man Wang, Institute for Translational Medicine, Medical College of Qingdao University, Dengzhou Road 38, Qingdao 266021, China.
E-mail: wangman@qdu.edu.cn

Correspondence: Kun Wang, Institute for Translational Medicine, Medical College of Qingdao University, Dengzhou Road 38, Qingdao 266021, China.
E-mail: wangk696@163.com
Exosomal cargoes can be delivered to the recipient cells via endocytosis, fusion with the cellular membrane, or ligand-receptor interaction. Exosomal cargoes represent a novel focus of investigation that would enrich our knowledge of the molecular mechanisms underlying the role of exosomes in cancer progression. A great variety of molecules can be incorporated into exosomes, including miRNAs, DNAs, RNAs, and proteins. Among these bioactive compositions, miRNAs have attracted substantial attention owing to their regulatory function in gene expression. miRNAs are short ncRNAs of approximately 24 nt in length. miRNAs function to suppress the expression of protein-coding genes at the post-transcriptional level. Moreover, miRNAs and their target genes constitute complicated regulatory networks that contribute to the fine-tuning of various biological processes, such as cell proliferation, differentiation, and death. More importantly, miRNA dysregulation is found to be associated with cancer progression.

miR-142-3p, miR-150, and miR-451 were found to be enriched in exosomes as compared to parent cells, demonstrating that these miRNAs were preferentially packaged into exosomes. Likewise, members of the let-7 miRNA family were more abundant in exosomes derived from gastric cancer (GC) cells than those derived from other cancer cells. Remarkably, some exosomal miRNAs (e.g., miR-21, let-7f, miR-20b, and miR-30e-3p) exhibited different expression levels in cancer patients compared with healthy controls. Thus, cells adopt specific sorting mechanisms that direct miRNA loading into exosomes, leading to the selective encapsulation of miRNAs into cell-secreted exosomes.

Four potential pathways for sorting miRNAs into exosomes are proposed (Figure 2). The neural sphingomyelinase 2 (nSMase2)-dependent pathway was found to guide miRNAs sorting into exosomes.
nSMase2 was the first molecule found to be associated with miRNA packaging into exosomes. Overexpression of nSMase2 caused an increase in the abundance of exosomal miRNAs. In contrast, inhibition of nSMase2 expression decreased the levels of exosomal miRNAs. The second sorting mechanism involves the sumoylated heterogeneous nuclear ribonucleoprotein (hnRNP)-dependent pathway. Three hnRNP family proteins (hnRNPA2B1, hnRNPA1, and hnRNPC) bound to exosomal miRNAs and induced the loading of miRNAs into exosomes. Specially, the sumoylated hnRNPA2B1 controlled the exosomal assortment of miRNAs by recognizing the GGAG motif in the 3'0 portion of miRNA sequences.

The third pathway depends on the 3’ end of the miRNA. The 3’ end of the miRNA sequence might contain an important sorting signal that contributed to guiding its incorporation into exosomes. The last sorting pathway is mediated by the miRNA-induced silencing complex (miRISC). The primary components of miRISC were found to co-localize with MVBS. Moreover, blockade of the turnover of MVBS into lysosomes resulted in excessive accumulation of miRISCs, while suppression of MVBS formation caused the loss of miRISC and relieved miRNA-mediated gene silencing. It was reported that exosomal miRNA sorting was controlled by cell activation-dependent changes of miRNA target abundance. Artificially elevating the cellular levels of miRNAs or their target miRNAs benefited miRNA enrichment in MVBS. Additionally, Argonaute 2 (Ago2), a component of the RISC, was also implicated in the exosomal assortment of miRNAs. Knockout of Ago2 could reduce the abundance of some exosomal miRNAs, including miR-142-3p, miR-150, and miR-451. Collectively, certain sequences present in miRNAs may favor their uptake into exosomes, and specific protein complexes may be involved in the loading of miRNAs into exosomes. Nevertheless, the sorting mechanisms of exosomal miRNAs remain unclear and deserve further investigation.

**Roles of Exosomal miRNAs in Cancer**

Exosomal miRNAs have been shown to exert multifaceted effects on cancer progression, including the regulation of cancer growth, angiogenesis and metastasis, domination of host immune responses, manipulation of cancer chemoresistance, and remodeling of the tumor microenvironment (Figure 3).

**Exosomal miRNAs Affect Cancer Cell Growth**

Proliferation is a crucial aspect of cancer progression that is commonly manifested by the deregulation of cell cycle-related proteins. Tumor growth is a contributing factor to the development of tumor angiogenesis and metastasis. Emerging evidence demonstrates that cancer-secreted exosomal miRNAs regulate cancer cell proliferation by targeting cell cycle-associated proteins or signaling pathways.

Exosomal miR-200b could be transmitted between colorectal cancer (CRC) cells, and it promoted the proliferation of recipient cells by...
lowering p27 expression. Exosomal miR-6869-5p could depress CRC cell proliferation and inhibit the production of inflammatory cytokines (interleukin-6 [IL-6] and tumor necrosis factor alpha [TNF-α]) in CRC cells by blocking the Toll-like receptor 4 (TLR4)/nuclear factor κB (NF-κB)-signaling pathway. Inhibition of oncogenic miR-21 sorting into exosomes suppressed the growth and migration of hepatocellular carcinoma (HCC) cells. Exosomal miR-9-3p restrained HCC cell proliferation by directly targeting fibroblast growth factor 5 (HBGF-5). Exosomal miR-1246, enriched in metastatic breast cancer cells, could be transferred into non-malignant breast cells. miR-1246 promoted the proliferation, migration, and drug resistance of breast cancer cells by downregulating cyclin-G2 (CCNG2). Exosomal miR-193a impeded the cell cycle progression and exerted an inhibitory effect on colon cancer cell proliferation by directly targeting cell cycle-associated protein 1 (Caprin1).

Moreover, exosomal miRNAs can orchestrate the apoptotic signaling pathway in cancer cells. For instance, exosomal miR-128 reduced the expression of Bcl-2-associated X protein (Bax) in recipient breast cancer cells. Exosomal miR-373 repressed the expression of estrogen receptor (ER) and inhibited the apoptosis of breast cancer cells. Human adipose mesenchymal stem cell (hAMSC)-derived exosomal miRNAs could induce the apoptosis of human ovarian cancer (OC) cells by upregulating apoptotic proteins (Bax, caspase 3, and caspase 9) and downregulating anti-apoptotic Bcl-2. Exosomal miR-101 promoted GC cell apoptosis by targeting anti-apoptotic myeloid cell leukemia-1 (Mcl-1).

**Figure 3. Summary of the Function of Exosomal miRNAs in Cancer**

Exosomal miRNAs play multifaceted roles in tumor initiation and development. Tumor cells could transfer exosomal miRNAs to surrounding tumor cells. In recipient tumor cells, exosomal miRNAs can control cell proliferation, invasion, and metastasis by orchestrating their downstream targets. Exosomal miRNAs mediate a special communication between tumor cells and endothelial cells, thus playing an important role in tumor angiogenesis. Drug-resistant tumor cells can transmit the resistant phenotype to drug-sensitive tumor cells through the horizontal transfer of exosomal miRNAs. In terms of mechanism, exosomal miRNAs mainly control the apoptotic or autophagic pathways, hence conferring chemoresistance to recipient tumor cells. Exosomal miRNAs serve as key messengers for exchanging information between tumor cells and immune cells (macrophages, T cells, and dendritic cells), contributing to the formation of a tumor-promoting, immunosuppressive microenvironment. In addition, exosomal miRNAs are instrumental for the cross-talk between tumor cells and CAFs within the tumor microenvironment. Tumor-derived exosomal miRNAs are capable of reprogramming and activating CAFs, thus facilitating tumorigenesis and tumor development. Exosomal miRNAs derived from adjacent CAFs in turn modulate the malignant phenotype of tumor cells.
of cell adhesion molecules (E-cadherin and β-catenin) with the concomitant acquisition of mesenchymal markers (N-cadherin and vimentin). Exosomal miRNAs serve as significant regulators in the EMT process. Exosomal miR-21 significantly increased the expression of Snail and vimentin and decreased the expression of E-cadherin, contributing to the induction of EMT-related changes in oral squamous cell carcinoma (OSCC) cells. Exosomal miR-1246 could repress the activities of N-cadherin and vimentin, hence restraining the EMT process in prostate cancer cells. The miR-200 family derived from malignant colon cancer negatively modulated EMT-inducing transcription factors, zinc finger E-box-binding homeobox 1 (ZEB1) and Snail2 (Slug). Exosomal miR-101 repressed GC cell invasion and migration by inhibiting ZEB1.

Exosomal miRNAs serve a crucial role in tumor-endothelial cross-talk, thereby regulating angiogenesis and cancer progression. HCC cell-derived exosomal miR-103 enhanced vascular permeability and promoted tumor metastasis by targeting various endothelial junction proteins (VE-cadherin, p120-catenin, and zonula occludens 1) in endothelial cells. Hypoxic leukemia cell-secreted exosomal miR-210 enhanced the angiogenic activity in endothelial cells by targeting the receptor tyrosine kinase ligand Ephrin-A3. Oppositely, exosomal miR-126 served a negative role in leukemia cell motility and adhesion by lowering the expression of C-X-C motif chemokine ligand 12 (CXCL12) and vascular cell adhesion molecule-1 (VCAM-1) in endothelial cells. Exosomal miR-210, released by metastatic breast cancer cells, could be transported to endothelial cells and enhanced the angiogenesis in recipient cells. Exosomal miR-23a secreted by nasopharyngeal carcinoma (NPC) cells promoted the growth, migration, and tube formation of endothelial cells, and it also enhanced the outgrowth of blood vessels by inhibiting testis-specific gene antigen 10 (TSGA10). In contrast, exosomal miR-9 suppressed NPC cell migration and angiogenesis by directly targeting midkine (MDK) and modulating the phosphoinositide-dependent protein kinase (PDK)/protein kinase B (Akt)-signaling pathway. Exosomal transfer of miR-23a from hypoxic hepatocarcinoma cells induced the angiogenesis in recipient endothelial cells by targeting sirtuin 1 (SIRT1). Similarly, exosomal miR-23a derived from hypoxic lung cancer cells suppressed the expression of prolyl hydroxylase (PHD) and tight junction protein zonula occludens-1 (ZO-1), thus enhancing vascular permeability and cancer trans-endothelial migration.

Exosomal miRNAs are able to affect the invasive and metastatic behaviors of cancer cells. miR-148a delivered by exosomes promoted glioblastoma (GBM) cell proliferation and metastasis via activating the signal transducer and activator of transcription 3 (STAT3) pathway by targeting cell adhesion molecule 1 (CADM1). Exosomal miR-423-5p could be internalized into GC cells and promoted cancer cell proliferation and migration by targeting suppressor of fused protein (SUFU). Exosomal miR-96 directly targeted LIM domain-only protein 7 (LMO7), and it enhanced the proliferation and migration of lung cancer cells. Liver kinase B1 (LKB1) was found to enhance lung cancer cell motility by reducing exosomal secretion of migration-suppressing miRNAs (miR-125a, miR-126, and let-7b). miR-222 could be transferred between tumor cells, and it enhanced tumor malignancy in melanoma through activation of the phosphoinositide 3-kinase (PI3K)/Akt pathway. Exosomal miR-6126 limited the invasion and migration of OC cells by inhibiting integrin-β1, a vital modulator of cancer cell metastasis. Exosomal miR-940 suppressed the proliferation, invasion, and migration of OC cells. Mechanistically, miR-940 directly targeted the proto-oncogene tyrosine-protein kinase (SRC). The transfer of tumor-suppressive miR-940 by cancer-derived exosomes might enable OC cells to maintain their invasiveness and tumorigenic phenotype. Exosomal miR-490 derived from mast cell (MC) blocked the epidermal growth factor receptor (EGFR)/Akt/extracellular signal-regulated kinase (ERK) 1/2 pathway in recipient HCC cells, which led to the attenuation of HCC cell migration. Exosomal delivery of miR-23b from the bone marrow inhibited the invasion and migration of breast cancer cells by inhibiting its target gene, myristoylated alanine-rich C kinase substrate (MARCKS).

Exosomal miRNAs derived from metastatic cancer cells may affect the behavior of less aggressive cancer cells or even normal cells. The let-7 family of miRNAs was more abundant in exosomes from highly invasive OC cells than lowly invasive OC cells. Exosome-mediated transfer of these miRNAs might be correlated with the invasive activity of OC cells. Exosomes derived from brain metastatic (BM) cancer cells could be taken up by non-BM cancer cells. De-regulated exosomal miRNAs (miR-210, miR-19a, and miR-29c) might contribute to the increased adhesive and invasive abilities of non-BM cells. Exosomal miR-342-3p and miR-1246 derived from highly metastatic OSCC cells could be transferred to poorly metastatic OSCC cells and promote the growth, migration, and invasion of recipient cancer cells. Remarkably, exosomal miR-1246 induced a highly metastatic phenotype in recipient OSCC cells by downregulating DENN/MADD domain-containing protein 2D (DENND2D). Exosomal miR-675 enriched in metastatic osteosarcoma (OS) cells could target calneuron1 (CALN1), and, thus, it modulated the invasion and migration of non-malignant fibroblast cells. miR-10b derived from metastatic breast cancer cells could be delivered into normal mammary epithelial cells through exosomes. The transferred miR-10b enhanced the invasive capability in mammary epithelial cells by reducing the expression of homeobox protein hox-D10 (HOXD10) and kruppel-like factor 4 (KLF4). miR-21 could be transferred from cigarette smoke extract (CSE)-transformed human bronchial epithelial (HBE) cells to normal HBE cells via exosomes. Moreover, exosomal miR-21 activated STAT3 and increased the expression of vascular endothelial growth factor (VEGF), contributing to the induction of angiogenesis and malignant transformation in HBE cells. Taken together, these studies demonstrate that exosomes from aggressive cancer cells spread malignant properties by a horizontal transfer of miRNAs.

Cancer cells commonly initiate metastasis by breaking away from their adjacent cells and intruding into neighboring tissues after having undergone an EMT process that changes their characteristics to acquire motility and invasiveness. The formation of blood vessels is essential for cancer growth and progression. Accumulating evidence reveals...
that exosomal miRNAs play a regulatory role in tumor metastasis by controlling the EMT process, angiogenesis, and invasion. It can be concluded that the intercellular communication mediated by exosomal miRNAs may represent a vital mechanism for cancer progression.

**Cancer-Derived Exosomal miRNAs Mediate Immunomodulation**
Exosomal miRNAs function as critical mediators in the cross-talk between cancer cells and macrophages. Tumor-associated macrophages (TAMs) are important components of the tumor microenvironment and play a vital role in cancer pathogenesis. Macrophages can be categorized into two classes (M1 and M2) according to their function.99 M1-polarized macrophages inhibit tumor growth whereas M2-polarized macrophages provide an immunosuppressive niche for tumor development and metastasis.100

Exosomal miR-let-7a-5p, miR-10a-5p, miR-1246, and miR-125b-5p derived from lung adenocarcinoma cells promoted macrophage re-polarization toward a more pro-inflammatory, anti-tumor M1 phenotype.101 Oppositely, exosomal miR-222-3p from epithelial ovarian cancer (EOC) induced macrophage polarization and differentiation to the M2 phenotype by fine-tuning the suppressor of cytokine signaling 3 (SOCS3)/STAT3 pathway, which further promoted the growth and metastasis of EOC.102 Likewise, exosomal miR-940 enriched in hypoxic EOC cells performed a tumor-promoting function in EOC by driving macrophage activation toward the M2 phenotype.103 Exosomal miR-301a-3p derived from hypoxic pancreatic cancer (PC) cells triggered the M2 polarization of macrophages via activation of the phosphatase and tensin homolog (PTEN)/PI3K signaling pathway.104 Consequently, exosomal miR-301a-3p increased the metastatic activity of PC cells. Exosomal miR-21 and miR-29a derived from non-small-cell lung cancer (NSCLC) could be taken up by TAMs.105 In recipient cells, miR-21 and miR-29a could initiate a TLR-mediated pro-metastatic inflammatory response that supported tumor development. Exosomal miR-1246 enriched in colon cancer cells induced the reprogramming of macrophages into a tumor-supporting state.106

Tumor-derived exosomal miRNAs facilitate tumor immunosuppression by driving the dysfunction of immune cells. NPC-derived exosomal miRNAs (hsa-miR-24-3p, hsa-miR-891a, hsa-miR-106a-5p, and hsa-miR-1908) impaired T cell proliferation and differentiation by targeting the mitogen-activated protein kinase 1 (MAPK1) and Janus kinase (JAK)/STAT pathways.107 In another study, exosomal miR-24-3p was confirmed to block T cell proliferation and differentiation through regulation of the ERK- and STAT-signaling pathways by directly targeting fibroblast growth factor 11 (FGF1).108 PC-derived exosomal miR-212-3p could be delivered to dendritic cells.109 Exosomal miR-212-3p suppressed the expression of regulatory factor X-associated protein (RFXAP) and major histocompatibility complex class II (MHC class II), which contributed to the immune tolerance of dendritic cells.

The immune cells, including macrophages, T cells, and dendritic cells, constitute a host defense system against cancer progression. Nevertheless, cancer cells have evolved to transfer their miRNAs to these immune cells via exosomes. Exosome-shuttled miRNAs play a critical role in reprogramming host immune cells, thereby facilitating immune dysfunction and cancer progression. The functional role of exosomal miRNAs in the reciprocal interplay between cancer cells and host immune system merits further investigation.

**Exosomal miRNAs Modulate Cancer Cell Resistance to Chemotherapy**
Exosomal miRNAs can alter the chemosensitivity of cancer cells by manipulating cellular signaling pathways. Exosomal miR-34a increased docetaxel sensitivity of prostate cancer cells partly by regulating Bcl-2.110 Exosomal transfer of miR-151a sensitized temozolomide (TMZ)-resistant GBM cells to TMZ by targeting X-ray repair cross-complementing 4 (XRCC4).111 The macrophage-derived exosomes (MDEs) markedly reduced the sensitivity of pancreatic ductal adenocarcinoma (PDAC) cells to gemcitabine.112 Further study indicated that exosomal miR-365 repressed the activation of gemcitabine in cancer cells by upregulation of the triphospho-nucleotide pool and activation of the enzyme cytidine deaminase. Exosomal miR-221/222 released by tamoxifen-resistant breast cancer cells could effectively inhibit the expression of its target genes p27 and ERO, thus conferring tamoxifen resistance to recipient cancer cells.113

The expression of miR-146a-5p was reduced in both NSCLC cells and exosomes during the process of cisplatin (DDP)-mediated drug resistance.114 Overexpression of miR-146a-5p could attenuate the resistant property of DDP-resistant NSCLC cells (A549/DDP) via blocking cellular autophagy by directly targeting autophagy-related gene 12 (Atg12). On the contrary, exosomal miR-100-5p derived from A549/DDP enhanced DDP resistance in recipient NSCLC cells by targeting the mammalian target of rapamycin (mTOR).115 Exosomal miR-21 could be transferred from M2 macrophages to GC cells, and it decreased the sensitivity of recipient cancer cells to DDP.116 Mechanistically, exosomal miR-21 repressed cell apoptosis and activated the PI3K/Akt signaling pathway by targeting PTEN.

Cancer chemoresistance is still an unsolved problem in cancer treatment. A small quantity of drug-resistant cancer cells will persist and survive following chemotherapy, leading to tumor recurrence in patients. Drug-resistant cancer cells can disseminate the resistant phenotype to drug-sensitive cells via exosomes. This leads to the formation of a large population of cancer cells that are unaffected by drug therapy. Remarkably, exosomal miRNAs function to modulate drug susceptibility of cancer cells mainly by regulating cell cycle-associated proteins or modifying cellular apoptosis and autophagy pathways. The contribution of exosomal miRNAs to the development of cancer chemoresistance is an emerging research area that requires systematic exploration.

**Exosomal miRNAs Are Involved in Shaping the Tumor Microenvironment**
Cancer-derived exosomal miRNAs are important participants in the cross-talk between tumor cells and cancer-associated fibroblasts...
(CAFs) within the tumor microenvironment. Breast cancer-secreted exosomal miR-105 could induce a metabolic program in CAFs by activating the MYC signaling.117 Exosomal miR-105 favored persistent tumor growth by adapting CAFs to a different metabolic environment. Human melanoma-derived exosomes (HMEXs) could be taken up by human adult dermal fibroblasts (HADF3).118 HMEX-derived miR-155 and miR-210 were essential for the promotion of glycolysis and suppression of oxidative phosphorylation (OXPHOS) in HADF cells. This promoted extracellular acidification and thus facilitated the formation of a pre-metastatic niche that supported tumor metastasis. Highly metastatic HCC cells could deliver miR-1247-3p to CAFs via exosomes.119 Exosomal miR-1247-3p activated the β1-integrin/NF-κB signaling in fibroblasts by targeting β-1,4-galactosyltransferase III (B4GALT3). Activated CAFs promoted cancer progression through the secretion of pro-inflammatory cytokines (IL-6 and IL-8). CRC-derived exosomal miR-10b directly targeted the p110α catalytic subunit of PI3K (PIK3CA) and repressed the PI3K/Akt/mTOR signaling pathway in fibroblasts.120 Consequently, exosomal miR-10b was capable of promoting CRC growth by activating the surrounding stromal cells to become CAFs.

On the other hand, exosomal miRNAs derived from adjacent stromal cells in the tumor microenvironment could modulate the malignant phenotype of cancer cells. For example, CAF-derived exosomes and their miRNA cargoes (miR-21, miR-143, and miR-378e) could induce the stemness and EMT phenotype in breast cancer cells.121 Exosomal miR-21 secreted by fibroblasts promoted CRC metastasis.122 Likewise, CAF- and cancer-associated adipocyte (CAA)-derived exosomal miR-21 caused the inhibition of cell apoptosis and induction of chemoresistance in OC by directly targeting apoptotic protease activating factor 1 (APAF1).123 CAF-released exosomal miR-451 promoted the migration of adjacent esophageal cancer cells.124 miR-320a could be transferred from CAFs to HCC cells via exosomes.125 miR-320a inhibited HCC cell proliferation, migration and metastasis by inhibiting its downstream target Pre-B cell leukemia homeobox 3 (PBX3). Similarly, CAF-derived exosomal miR-148b could be transferred to endometrial cancer cells, and it inhibited cancer metastasis by targeting DNA methyltransferase1 (DNMT1).126

Cancer-derived exosomal miRNAs serve as signaling molecules to provide a suitable niche for cancer progression. Exosomal miR-503 promoted polarization of the microglia from a tumor-suppressive M1 to a tumor-promoting M2 phenotype.127 This contributed to brain metastasis in breast cancer. Tumor cells could interact with multiple different cell types, including osteoclasts, osteoblasts, and MSCs, leading to an osteolytic or osteoblastic phenotype.128 Prostate cancer-derived exosomal hsa-miR-940 induced the osteogenic differentiation of MSCs by controlling the expression of ARHGAP1 and FAM134A. hsa-miR-940 also promoted extensive osteoblastic lesions in the bone metastatic microenvironment. Exosomal let-7 miRNAs derived from metastatic GC cells exerted a tumor-suppressive function by targeting oncopgenes, including rat sarcoma (RAS) and high mobility group A2 (HMGA2).129 Metastatic GC cells released exosomal let-7 miRNAs into the extracellular environment to maintain their oncogenic characteristics.

Exosomal miRNAs derived from the microenvironment in turn affect tumor development. Exosomes derived from TNF-like weak inducer of apoptosis (TWEAK)-stimulated macrophages (TMs) could be transferred to EOC cells.129 TMs suppressed the metastasis of EOC cells via exosomal transfer of miR-7 to EOC cells. MSC-derived exosomal miR-100 possessed anti-angiogenic activity during tumorigenesis by inhibiting VEGF expression in recipient breast cancer cells.130 Exosomal miR-140 released by preadipocytes inhibited the tumorigenesis and migration of breast cancer cells by targeting sex determining region Y-box 2 (SOX2)/SOX9.131 It was reported that the oncogenic miR-221 derived from GC-derived MSCs (GC-MSCs) promoted the proliferation and migration of recipient GC cells.132 Astrocyte-derived exosomal miR-19a could be transferred to brain metastatic tumor cells, and it promoted tumor growth through the downregulation of PTEN.133 Therefore, targeting the tumor microenvironment might represent a promising therapeutic approach to prevent tumor progression. The intercommunication between tumor cells and the surrounding microenvironment is significant for tumor occurrence and development. The tumor microenvironment is composed of multiple types of non-tumor cells, including fibroblasts, MSCs, and infiltrating immune cells, all of which can communicate with tumor cells. Exosomal miRNAs play a regulatory role in the establishment of a tumor-supportive or tumor-suppressive milieu by reprogramming the cells within the tumor microenvironment. However, the molecular mechanisms by which exosomal miRNAs remodel the tumor microenvironment are not fully elucidated and await deep exploration in the future.

**Exosomal miRNAs Serve as Potential Biomarkers for Cancer Diagnosis and Prognosis**

Exosomal miRNAs display different expression patterns between cancer patients and healthy individuals. Moreover, exosomal miRNAs can indicate tumor progression, severity, and aggressiveness. Exosomal miRNAs have potential as promising cancer biomarkers for clinical use. Exosomal miR-181b-5p, miR-361b-5p, miR-10b-5p, and miR-320b and miR-320b were able to efficiently distinguish NSCLC patients from non-NSCLC individuals.134 These miRNAs might function as highly sensitive, non-invasive biomarkers for early NSCLC diagnosis. Exosomal miR-451a, miR-21, and miR-4257 were highly expressed in NSCLC patients compared with healthy individuals.135,136 These miRNAs were strongly associated with tumor progression, recurrence, and poor prognosis in NSCLC patients. Summarizing, they served as potential predictive biomarkers for NSCLC.

Exosomal miR-21 and miR-1246 were upregulated in patients with esophageal squamous cell carcinoma (ESCC) compared with healthy controls.137,138 They were positively associated with tumor aggressiveness and progression. Moreover, serum miR-1246 could distinguish ESCC patients from healthy controls with relatively high...
miRNAs could distinguish ccRCC patients from healthy individuals. Additionally, the prognostic values of exosomal miRNAs have been reported, suggesting that exosomal miR-21 may be a promising biomarker for multiple types of cancer. Further study is warranted to validate the clinical significance of exosomal miR-21 in cancer.

Exosomal miR-6803-5p, miR-17-5p, and miR-92a-3p were significantly elevated in the sera from CRC patients when compared to healthy controls. In contrast, exosomal miR-548c-5p was obviously downregulated in CRC patients. High levels of exosomal miR-17-5p and miR-92a-3p were remarkably correlated with the pathologic grade and stage of CRC patients. Uregulated miR-6803-5p and downregulated miR-548c-5p were associated with tumor progression and poor prognosis in CRC patients. Therefore, these exosomal miRNAs might be promising non-invasive biomarkers for CRC diagnosis and prognosis.

Serum exosomal miR-301a level was positively associated with disease progression and overall survival in GBM patients. This miRNA might function as an effective biomarker for glioma. Exosomal miR-223-3p level in the sera of patients with breast cancer was significantly higher than that of healthy controls. Its expression was tightly associated with the malignancy of breast cancer, suggesting that exosomal miR-223-3p might be a useful biomarker for the early detection of invasive breast cancer. Exosomal miR-210 and miR-1233 were significantly upregulated in clear-cell renal cell carcinoma (ccRCC) patients compared with healthy individuals. These miRNAs could distinguish ccRCC patients from healthy individuals with high sensitivity and specificity. Exosomal miR-210 and miR-1233 might be utilized as diagnostic biomarkers for renal cancer.

Additionally, the prognostic values of exosomal miRNAs have been investigated in several types of cancer. The serum levels of exosomal miR-200b and miR-200c could differentiate between benign and malignant EOC. Upregulation of exosomal miR-200b and miR-200c correlated with tumor progression and poor overall survival in EOC patients. Exosomal miR-638 level was decreased in the sera of HCC patients. Serum exosomal miR-638 was negatively correlated with HCC progression. Its downregulation predicted poor prognosis and low overall survival in HCC patients. Serum exosomal miR-638 might be a prospective circulating biomarker for HCC. Exosomal miR-4772-3p could discriminate colon cancer patients with recurrence from non-recurrent patients. Exosomal miR-4772-3p might serve as a prognostic biomarker for colon cancer patients with tumor recurrence. Exosomal miR-let-7b and miR-18a were significantly correlated with poor outcomes in patients with multiple myeloma (MM). miR-let-7i-5p, miR-26a-1-3p, and miR-615-3p were correlated with the overall survival of patients with metastatic RCC. Therefore, exosomal miRNAs may represent non-invasive biomarkers for cancer prognosis.

Early diagnosis of cancer is critical to improve the survival rate of cancer patients. Therefore, discovering effective biomarkers is of great importance. At present, blood-based markers for cancer diagnosis, such as carcinoembryonic antigen (CEA) and α-fetoprotein (AFP), lack sufficient sensitivity, specificity, and accuracy. Exosomal miRNAs display great promise as useful cancer biomarkers owing to their high stability, easy accessibility, and wide presence in body fluids. Large-scale studies are required to better define the potential clinical utility of exosomal miRNAs as diagnostic and prognostic biomarkers in cancer. The expression level of exosomal miRNAs is linked to tumor type, stage, and other clinical variables. Accordingly, it is critical to confirm the utilized range of exosomal miRNAs and figure out their associations with conventional cancer biomarkers. Moreover, standardized techniques for exosome separation and detection are not available. A set of stable inner reference genes for accurate quantification of exosomal miRNAs remains to be developed. These problems must be solved before the clinical utilization of exosomal miRNAs.

**Exosome-Mediated miRNA Delivery for Cancer Treatment: Challenges and Future Prospects**

Increasing evidence reveals that exosome-mediated delivery of miRNAs is tightly associated with carcinogenesis and cancer progression. Targeting the biogenesis of exosome may be a potential approach to treat cancer. Aminoflur inhibits exosome production and blunted the T cell-suppressive function of myeloid-derived suppressor cells (MDSCs) in vivo, thereby enhancing the anti-tumor efficacy of the chemotherapeutic drug. Prohibiting the uptake of exosomes by recipient cells may represent another strategy to impair exosome function. Tumor-derived exosomes containing oncogenic EGFR could be ingested by endothelial cells, and, thus, they supported tumor growth and angiogenesis. Diannexin abrogated these effects via inhibiting the uptake of tumor-derived exosomes by endothelial cells. Nevertheless, exosome-based therapeutics may also interfere with the physiological function of non-tumor cell-derived exosomes. This results in severe and even unpredictable side effects. The use of exosomes as carriers to deliver tumor-suppressive miRNAs represents an alternative therapeutic strategy for the treatment of cancer.

A variety of miRNAs have been confirmed to play an inhibitory role in cancer progression. Therefore, miRNAs hold promise as therapeutic targets for cancer. The major challenge of applying miRNAs for therapeutic purpose is that exogenous miRNAs are quickly degraded by ribonucleases that are highly active in the blood. Exosome-shuttled miRNAs can be protected from enzymatic degradation and stably exist in the circulation. Exosomes can deliver miRNAs to local or remote recipient cells. Notably, exosome-mediated delivery of miRNAs might provide a distant and more bioactive pool of circulating miRNAs compared to those transported by ribonucleoprotein complexes. Due to their stable and non-toxic characteristics, exosomes would be ideal candidate carriers for the delivery of anti-tumor miRNAs. Nevertheless, several issues remain to be addressed before the clinical application of exosomes as anti-carcinogenic therapeutic tools.
It is necessary to identify the most robust cellular source of exosomes appropriate for clinical use. Exosomes can be obtained from multiple types of human cells. There is a lack of comparative studies on how the cellular origin of exosomes influences their therapeutic efficacy. Thus, it is uncertain which source is the most optimal in terms of exosome isolation. At present, the isolation methods of exosomes are expensive, time consuming, and labor intensive. Reproducible and low-cost techniques for mass production of exosomes are urgently required. The amount of nucleic acids in exosomes varies greatly from patient to patient. Moreover, distinct isolation approaches or different sources may give quite different results. It is critical to verify the physiologically relevant dosage of exosomal miRNAs required for intercellular communication. Further research is warranted to determine whether the compositional differences between exosomes derived from distinct origins reflect their functions.

A major hurdle in the clinical application of exosomes has been the lack of feasible approaches to achieve pure exosomes without contamination by similar-sized particles. Therefore, improved purification and identification protocols for exosomes need to be developed. The requirements for the characterization of pure exosomes should be determined. Given that exosomes contain a variety of proteins and carry MHC molecules, exogenous exosomes may elicit an immune reaction, leading to their rapid elimination in the host. Exosomes with low immunogenicity are more suitable for therapeutic applications. Future efforts should be directed to identify and remove pro-tumorigenic components from exosomes. It will be difficult to control the exact component of cell-derived natural exosomes. Alternatively, determination of the identity of exosomal composition is critical for large-scale manufacture of synthetic exosome mimetics that may have a promising applicability in gene therapy. Different recipient cells might display distinct responses to exosomes, suggesting that the receptor specificity is an important factor for the uptake of exosomes. Identification of tumor cell-specific receptor repertoires for targeted delivery of miRNAs by exosomes is an essential step toward clinical cancer therapy. Furthermore, a better understanding of exosome biology and its role in cancer progression will be helpful to predict the safety and therapeutic efficacy of exosomes in vivo.

The impact of exosome-shuttled miRNAs on tumor progression was previously disclosed. Exosome-formed miR-143 could be transferred from MSCs to OS cells. Exosomal miR-143 dramatically inhibited the migration of recipient OS cells. However, the delivery efficiency of exosome-formed miR-143 was low. Moreover, researchers failed to load miRNAs into exosomes in vitro. Efficient encapsulation of candidate miRNAs in exosomes is a predominant challenge that remains to be overcome. The factors (e.g., solubility and charge distribution) that affect miRNA entrapment efficiency must be carefully delineated. Specifically, the methods for accurately defining the amount of loaded miRNA need to be ascertained. Moreover, the pathways by which anti-tumor miRNAs exert their function must be well determined to prevent the risk of off-target effects.

Exosomes loaded with miRNAs can be delivered either systemically or through local inoculation into the tumor tissue. For the treatment of easily accessible tumors (e.g., breast cancer and melanoma), exosomes can be delivered by local injection, attenuating the risk of off-target effects and dissemination. In contrast, for the therapeutic intervention on other types of tumors, exosomes should be delivered by systemic administration. An in-depth investigation into the pharmacokinetic profile and biodistribution of exosomes delivered by distinct routes and modalities is warranted before their clinical translation. Since the clearance of exosomes predominantly occurs in the liver and kidney, the impacts of administrated exosomes on the physiological function of these organs deserve deep investigation. In addition, further studies are required to explore whether different administration routes could affect the efficacy of exosomal miRNA-mediated therapeutics.

Regular injections of miRNA-loaded exosomes may be essential for maintaining the miRNA effect in cancer patients. The verification of optimal administration times is worthwhile. To favor the tissue-specific delivery of miRNA cargoes, the surface of exosomes could be engineered to improve their tumor-targeting capability. Targeting ligands, peptides, and antibody fragments attached to the surface proteins of exosomes should be designed and produced. As the procedures for cloning and recombinant expression are time consuming, highly efficient targeting approaches should be developed. For instance, targeting peptides or ligands could be directly linked to the exosomal surface through chemical conjugation. Furthermore, iterative clinical trials must be conducted before the clinical application of miRNA-loaded exosomes. Collectively, applying exosome-delivered miRNAs to clinical cancer therapy is a challenging but intriguing effort that needs further investigation.

Conclusions
Exosomes are a novel class of intercellular signal mediators that are engaged in the occurrence and progression of cancer. Exosomes contain a wide range of biological molecules, including lipids, proteins, and nucleic acids. miRNAs play an important role in cancer progression and hold promise as diagnostic and prognostic biomarkers for cancer. The function of exosomal miRNAs in cancer pathogenesis has been a research hotspot over the past few years. Increasing evidence indicates that exosomal miRNAs serve a regulatory role in cancer growth, angiogenesis, invasion, and metastasis. Moreover, exosomal miRNAs can modulate the chemoresistance of cancer cells. For the purpose of retaining cancer cells’ sensitivity to anti-cancer drugs, the mechanisms behind exosomal miRNA-regulated cancer chemoresistance need to be further delineated.

Exosomal miRNAs serve as signaling molecules in the communication between tumor cells and the tumor microenvironment. The detailed mechanisms underlying the biogenesis, secretion, and uptake of exosomes still await adequate elucidation. The regulatory role of exosomal miRNAs in the shaping of the tumor microenvironment is worthy of deeper exploration. Exosomal miRNAs can affect the expression of immune-related genes and reprogram the immune
cells. Nevertheless, the study on the involvements of exosomal miRNAs in modulating host immune responses is only in its infancy. Further studies are needed to gain a better understanding of the mechanisms underlying exosomal miRNA-mediated immunomodulation. Therefore, a great research effort is required to completely unveil the role of exosomal miRNAs in carcinogenesis and cancer progression. An in-depth investigation into the contributions of exosomal miRNAs to cancer pathogenesis will provide tremendous opportunities for the clinical translation of exosome-mediated miRNA delivery in targeted cancer therapy.

AUTHOR CONTRIBUTIONS
M.W. and K.W. conceived and designed the study. M.W. wrote the manuscript. F.Y. and H.D. prepared the figures. Y.W., P.L., and K.W. edited the manuscript. All authors read and approved the final manuscript.

CONFLICTS OF INTEREST
The authors declare no competing interests.

ACKNOWLEDGMENTS
This work was supported by the National Natural Science Foundation of China (81701991) and the Applied Basic Research Programs of Qingdao, China (17-1-1-59-jh).

REFERENCES
1. Abak, A., Abbarn, A., and Rahimzadeh, S. (2018). Exosomes in cancer: small vesicular transporters for cancer progression and metastasis, biomarkers in cancer therapeutics. Peer J 6, e4763.
2. Pap, E., Pällinger, E., and Falus, A. (2011). The role of membrane vesicles in tumorgenesis. Curr. Rev. Oncol. Hematol. 79, 213–223.
3. van Niel, G., Raposo, G., Candalh, C., Boussac, M., Hershberg, R., Cerf-Bensussan, N., and Heyman, M. (2001). Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterology 121, 337–349.
4. Blancard, N., Lankar, D., Faure, F., Regnault, A., Dumont, C., Rappo, G., and Hivroz, C. (2002). TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. J. Immunol. 168, 3235–3241.
5. Kharaziha, P., Ceder, S., Li, Q., and Panaretakis, T. (2012). Tumor cell-derived exosomes: a message in a bottle. Biochim. Biophys. Acta 1826, 103–111.
6. Dahtas, M., Margolick, J.B., Lopez, J., and Bream, J.H. (2011). Multiplex measurement of proinflammatory cytokines in human serum: comparison of the Meso Scale Discovery electrochemiluminescence assay and the Cytofometric Bead Array. J. Immunol. Methods 372, 71–77.
7. Fèverier, B., and Račoš, G. (2004). Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr. Opin. Cell Biol. 16, 415–421.
8. Caby, M.P., Lankar, D., Vincendeau-Scherrer, C., Rappo, G., and Bonnerot, C. (2005). Exosomal-like vesicles are present in human blood plasma. Int. Immunol. 17, 879–887.
9. Pitkun, T., Shen, R.F., and Kneppe, M.A. (2004). Identification and proteomic profiling of exosomes in human urine. Proc. Natl. Acad. Sci. USA 101, 13368–13373.
10. Ogawa, Y., Kani-Azuma, M., Akimoto, Y., Kawakami, H., and Yano, H. (2008). Exosome-like vesicles with dipeptidyl peptidase IV in human saliva. Biol. Pharm. Bull. 31, 1059–1062.
11. Desdin-Micó, G., and Mittelbrunn, M. (2017). Role of exosomes in the protection of cellular homeostasis. Cell Adhes. Migr. 11, 127–134.
12. Bobrie, A., Colombo, M., Raposo, G., and Théry, C. (2011). Exosome secretion: molecular mechanisms and roles in immune responses. Traffic 12, 1659–1668.
13. Bullock, M.D., Silva, A.M., Kanliklier-Unaldi, P., Filant, J., Rushed, M.H., Sood, A.K., Lopez-Berestein, G., and Calin, G.A. (2015). Exosomal Non-Coding RNAs: Diagnostic, Prognostic and Therapeutic Applications in Cancer. Noncoding RNA J 3, 53–68.
14. Yang, C., and Robbins, P.D. (2011). The roles of tumor-derived exosomes in cancer pathogenesis. Clin. Dev. Immunol. 2011, 842849.
15. Kahler, C., and Kalluri, R. (2013). Exosomes in tumor microenvironment influence cancer progression and metastasis. J. Mol. Med. (Berl) 91, 431–437.
16. Taylor, D.D., and Gercel-Taylor, C. (2011). Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin. Immunopathol. 33, 441–454.
17. Jero, M., Valenti, R., Huber, V., Filipazzi, P., Parmiani, G., Fais, S., and Rivoltini, L. (2008). Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ. 15, 80–88.
18. Zhao, L., Liu, W., Xiao, J., and Cao, B. (2015). The role of exosomes and “exosomal shuttle microRNA” in tumorgenesis and drug resistance. Cancer Lett. 356 (2 Pt B), 339–346.
19. Liz, J., and Esteller, M. (2016). IncRNAs and microRNAs with a role in cancer development. Biochim. Biophys. Acta 1859, 169–176.
20. Catalanotto, C., Cogoni, C., and Zardo, G. (2016). MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions. Int. J. Mol. Sci. 17, 1712.
21. Hayashi, T., Lombaert, I.M., Hauser, B.R., Patel, V.N., and Hoffman, M.P. (2017). Exosomal MicroRNA Transport from Salivary Mesenchyme Regulates Epithelial Progenitor Expansion during Organogenesis. Dev. Cell 40, 95–103.
22. Cho, Y.E., Kim, S.H., Lee, B.H., and Baek, M.C. (2017). Circulating Plasma and Exosomal microRNAs as Indicators of Drug-Induced Organ Injury in Rodent Models. Biomed. Ther. (Seoul) 25, 367–373.
23. Palmiero, E.I., de Campos, S.G., Campos, M., de Souza, N.C., Guerreiro, I.D., Carvalho, A.L., and Marques, M.M. (2011). Mechanisms and role of microRNA deregulation in cancer onset and progression. Genet. Mol. Biol. 34, 363–370.
24. Li, C., Gao, Y., Zhang, K., Chen, J., Han, S., Feng, B., Wang, R., and Chen, L. (2015). Multiple Roles of MicroRNA-100 in Human Cancer and its Therapeutic Potential. Cell Physiol. Biochem. 37, 2143–2159.
25. Liu, H. (2012). MicroRNAs in breast cancer initiation and progression. Cell. Mol. Life Sci. 69, 3587–3599.
26. Li, S.D., Zhang, J.R., Wang, Y.Q., and Wan, X.P. (2010). The role of microRNAs in ovarian cancer initiation and progression. J. Cell. Mol. Med. 14, 2240–2249.
27. Ferracin, M., Veronese, A., and Negrini, M. (2010). Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev. Mol. Diagn. 10, 297–308.
28. Chen, X., Liang, H., Zhang, J., Yus, K., and Zhang, C.Y. (2012). Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein Cell 3, 28–37.
29. Valadi, H., Ekström, K., Bossios, A., Sjostrand, M., Lee, J.J., and Lovrát, J.O. (2007). Exosome-mediated transfer of miRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654–659.
30. Rahibowits, G., Gercel-Taylor, C., Day, I.M., Taylor, D.D., and Kloekcker, G.H. (2009). Exosomal microRNA: a diagnostic marker for lung cancer. Clin. Lung Cancer 10, 42–46.
31. Brinton, L.T., Sloane, H.S., Kester, M., and Kelly, K.A. (2015). Formation and role of exosomes in cancer. Cell. Mol. Life Sci. 72, 659–671.
32. Gruenberg, J., and van der Goot, F.G. (2006). Mechanisms of pathogen entry through the endosomal compartments. Nat. Rev. Mol. Cell Biol. 7, 495–504.
33. Kowal, J., Tkach, M., and Théry, C. (2014). Biogenesis and secretion of exosomes. Dev. Cell 34, 723–737.
34. Wollert, T., and Hurley, J.H. (2010). Molecular mechanism of multivesicular body biogenesis by ESCRT complexes. Nature 464, 864–869.
35. Baietti, M.F., Zhang, Z., Mortier, E., melchior, A., Degest, G., Gerraerts, A., Ivarsson, Y., Depoortere, F., Coomans, C., Vermeiren, E., et al. (2012). Syndecan-4/SYNTENIN-ALIX regulates the biogenesis of exosomes. Nat. Cell Biol. 14, 677–685.
36. Hurley, J.H., and Odorizzi, G. (2012). Get on the exosome bus with ALIX. Nat. Cell Biol. 14, 654–655.

www.moleculartherapy.org
37. Razi, M., and Futter, C.E. (2006). Distinct roles for Tsg101 and Hrs in multivesicular body formation and inward vesiculation. Mol. Biol. Cell 17, 3469–3483.
38. Bobrie, A., Krumeich, S., Reyal, F., Recchi, C., Moita, L.F., Seabra, M.C., Ostromski, M., and Thery, C. (2012). Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Cancer Res. 72, 4920–4930.
39. Ostromski, M., Carbo, N.B., Krumeich, S., Fanget, I., Raposo, G., Savina, A., Moita, C.F., Schauer, K., Hume, A.N., Freitas, R.P., et al. (2010). Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. 12, 19–28.
40. Cucco, E., Racchetti, G., and Meldolesi, J. (2009). Shedding microvesicles: artefacts no more. Trends Cell Biol. 19, 43–51.
41. Südhof, T.C., and Rothman, J.E. (2009). Membrane fusion: grappling with SNARE no more. Trends Cell Biol. 19, 43–51.
42. Chen, X., Liang, H., Zhang, J., Zeng, K., and Zhang, C.Y. (2012). Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol. 22, 125–132.
43. Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297.
44. Ambros, V. (2004). The functions of animal microRNAs. Nature 431, 355–357.
45. Kim, V.N., Han, J., and Siomi, M.C. (2009). Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol. 10, 126–139.
46. Miska, E.A. (2005). How microRNAs control cell division, differentiation and death. Curr. Opin. Genet. Dev. 15, 563–568.
47. Hwang, H.W., and Mendell, J.T. (2006). MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br. J. Cancer 94, 776–780.
48. Lee, J.W., Choi, C.H., Choi, J.J., Park, Y.A., Kim, S.I., Hwang, S.Y., Kim, W.Y., Kim, T.J., Lee, J.H., Kim, B.G., and Bae, D.S. (2008). Altered MicroRNA expression in cervical carcinomas. Clin. Cancer Res. 14, 2535–2542.
49. Taturi, A., Leivonen, S.K., Leduc, I., Stenfeldt, I., Ragle Aure, M., Geisler, J., Mäkelä, R., Nord, S., Rist, M.L., Yakini, Z., et al. (2014). Deregulation of cancer-related microRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis 35, 76–85.
50. Ambos, S., Prueitt, R.L., Yi, M., Hudson, R.S., Howe, T.M., Petrocca, F., Wallace, T.A., Liu, C.G., Volmina, S., Calin, G.A., et al. (2008). Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 68, 6162–6170.
51. Guduric-Fuchs, J., Connor, A., Camp, B., O'Neill, C.L., Medina, R.J., and Simpson, D.A. (2012). Selective extracellular vesicle-mediated export of an overlapping set of microRNAs from multiple cell types. BMC Genomics 13, 357.
52. Ohshima, K., Inoue, K., Fujiwara, A., Hatakeyama, K., Kanto, K., Watanabe, Y., Muramatsu, K., Fukuda, Y., Ogura, S., Yamaguchi, K., and Mochizuki, T. (2010). Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS ONE 5, e13247.
53. Skog, J., Würdinger, T., van Rijn, S., Meijer, D.H., Meijer, D.H., Gainche, L., Sena-Esteves, M., Simpson, D.A., Medina, R.J., and Yakhini, Z., et al. (2009). Selective extracellular vesicle-mediated export of an overlapping set of microRNAs from multiple cell types. BMC Genomics 10, 1470–1476.
54. Silva, J., García, V., Zaballos, Á., Provencio, M., Lombardía, L., Almonacid, L., García, J.M., Domínguez, G., Peña, C., Diaz, R., et al. (2011). Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with stage. Cancer Res. 71, 1283–1289.
55. Zeng, J., Li, X., Liu, Y., Liu, M., Cui, S., Wang, D., Zhang, C.Y., Ren, Z.J., and Li, L. (2016). MicroRNA-193a promotes colon cancer progression. Nat. Commun. 7, 12578.
56. Li, X.J., Ren, Z.J., Tang, J.H., and Yu, Q. (2017). Exosomal MicroRNA MR-1246 Promotes Cell Proliferation, Invasion and Drug Resistance by Targeting CCNG2 in Breast Cancer. Cell. Physiol. Biochem. 44, 1741–1748.
57. Teng, Y., Ren, Y., Xu, M., Mu, J., Samykutty, A., Zhubang, X., Deng, Z., Kumar, A., Zhang, L., Merchant, M.L., et al. (2017). MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression. Nat. Commun. 8, 14448.
58. Wei, Y., Li, M., Cui, S., Wang, D., Zhang, C.Y., Ren, Z.J., and Li, L. (2016). Shikonin Inhibits the Proliferation of Human Breast Cancer Cells by Reducing Tumor-Derived Exosomes. Molecules 21, 777.
59. Eichelseder, C., Stückerth, I., Müller, V., Milde-Langosch, K., Wikman, H., Pantel, K., and Schwarzenbach, H. (2014). Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget 5, 9650–9663.
60. Reza, A.M.T., Choi, Y.J., Yasuda, H., and Kim, J.H. (2016). Human adipose mesenchymal stem cell-derived exosomal microRNAs are critical factors for inducing anti-proliferation signalling to A2780 and SKOV-3 ovarian cancer cells. Sci. Rep. 6, 34894.
61. Imamura, T., Komatsu, S., Ichikawa, D., Miyamae, M., Okajima, W., Ohashi, T., Kiuchi, J., Nishiikeppu, K., Kousaka, T., Konishi, H., et al. (2017). Low plasma levels of miR-101 are associated with tumor progression in gastric cancer. Oncotarget 8, 106558–106550.
62. Brabletz, T., Kalluri, R., Nieto, M.A., and Weinberg, R.A. (2018). EMT in cancer. Nat. Rev. Cancer 18, 128–134.
63. Li, L., Li, C., Wang, S., Wang, Z., Jiang, J., Wang, W., Li, X., Chen, J., Liu, K., Li, C., and Zhu, G. (2016). Exosomes Derived from Hypoxic Oral Squamous Cell Carcinoma Cells Deliver miR-21 to Normoxic Cells to Elicit a Prometastatic Phenotype. Cancer Res. 76, 1770–1780.
64. Bhagirath, D., Yang, T.L., Bucay, N., Sekhon, K., Majid, S., Shahbiry, V., Dahra, T., Tanaka, Y., and Saini, S. (2018). microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer. Cancer Res. 78, 1833–1844.
65. Senfter, D., Holzner, S., Karpousi, M., Stab, I., Alwal, A., Huttner, N., Krieger, S., Brenner, S., Jager, B., Krupitza, G., et al. (2015). Loss of miR-200 family in 5-flurouracil resistant colon cancer drives lymphendothelial invasiveness in vitro. Hum. Mol. Genet. 24, 3689–3698.
66. Feng, J.H., Zhang, Z.J., Shang, L.R., Luo, Y.W., Lin, Y.F., Yuan, Y., and Zhuang, S.M. (2018). Hepatoma cell-secreted exosomal microRNA-103 increases vascular...
permeability and promotes metastasis by targeting junction proteins. Hepatology 68, 1459–1475.

77. Tadokoro, H., Umeyu, T., Ohyashiki, K., Hirano, T., and Ohyashiki, J.H. (2013). Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J. Biol. Chem. 288, 34343–34351.

78. Taverna, S., Amodeo, V., Saiava, L., Russo, A., GiolambUMO, M., De Leo, G., and Alessandro, R. (2014). Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and migratory abilities of chronic myelogenous leukemia cells. Mod. Cancer 13, 169.

79. Bao, L., You, B., Shi, S., Shan, Y., Zhang, Q., Yue, H., Zhang, J., Zhang, W., Shi, Y., Liu, Y., et al. (2018). Metastasis-associated miR-23a from nasopharyngeal carcinoma-derived exosomes mediates angiogenesis by repressing a novel target gene TSGA10. Oncogene 37, 2873–2889.

80. Lu, J., Liu, Q.H., Wang, F., Tan, J.J., Deng, Y.Q., Peng, X.H., Liu, X., Zhang, B., Xu, X, and Li, X.P. (2016). Exosomal miR-9 inhibits angiogenesis by targeting MKD and regulating PDK/AKT pathway in nasopharyngeal carcinoma. J. Exp. Clin. Cancer Res. 37, 147.

81. Sruthi, T.V., Edatt, L., Raji, G.R., Kunhiraman, H., Shankar, S.S., Shankar, V., Lu, J., Liu, Q.H., Wang, F., Tan, J.J., Deng, Y.Q., Peng, X.H., Liu, X., Zhang, B., Xu, X, and Li, X.P. (2016). Exosomal miR-9 inhibits angiogenesis by targeting MKD and regulating PDK/AKT pathway in nasopharyngeal carcinoma. J. Exp. Clin. Cancer Res. 37, 147.

Struthi, T.V., Edatt, L., Raji, G.R., Kunhiraman, H., Shankar, S.S., Shankar, V., Ramachandran, V., Poyyakkara, A., and Kumar, S.V.B. (2018). Horizontal transfer of miR-23a from hypoxic tumor cells can induce angiogenesis. J. Cell. Physiol. 233, 3498–3514.

82. Hsu, Y.L., Hung, Y.J., Chang, W.A., Lin, Y.S., Pan, Y.C., Tsai, P.H., Wu, C.Y., and Kuo, P.L. (2017). Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene 36, 4929–4942.

83. Cai, Q., Zha, A., and Gong, L. (2018). Exosomes of glioma cells deliver miR-148a to promote proliferation and metastasis of glioblastoma via targeting CADM1. Bull. Cancer 105, 643–651.

84. Yang, H., Fu, H., Wang, B., Zhang, X., Mao, J., Li, X., Wang, M., Sun, Z., Qian, H., and Xu, W. (2018). Exosomal miR-423-5p targets SUFU to promote cancer growth and metastasis and serves as a novel marker for gastric cancer. Mol. Carcinog. 57, 1223–1236.

85. Wu, H., Zhou, J., Mei, S., Wu, D., Mu, Z., Chen, B., Xie, Y., Ye, Y., and Liu, J. (2017). Circulating exosomal microRNA-96 promotes cell proliferation, migration and drug resistance by targeting LMO7. J. Cell. Mol. Med. 21, 1228–1226.

86. Zhang, C., Xiao, X., Chen, M., Aldhaaree, H., Chen, Y., and Long, W. (2018). Liver kinase B1 restoration promotes exosome secretion and motility of lung cancer cells. Oncol. Rep. 39, 376–382.

87. Felcetti, F., De Feo, A., Coscia, C., Puglisi, R., Pedini, F., Pasquini, L., Bellenghi, M., Errico, M.C., Pagani, E., and Carè, A. (2016). Exosome-mediated transfer of miR-222 is sufficient to increase tumor malignancy in melanoma. J. Transl. Med. 14, 56.

88. Kantikilic, P., Rashid, M.H., Bayraktar, R., Mitra, R., Ivan, C., Aslan, B., Zhang, X., Filan, J., Silva, A.M., Rodriguez-Aguayo, C., et al. (2016). Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. Cancer Res. 76, 7194–7207.

89. Rashid, M.H., Kantikilic, P., Rodriguez-Aguayo, C., Pichler, M., Bayraktar, R., Bayraktar, L., Ivan, C., Filan, J., Silva, A., Aslan, B., et al. (2017). Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget 8, 20145–20164.

90. Xiong, L., Zhen, S., Yu, Q., and Gong, Z. (2017). HCV-E2 inhibits hepatocellular carcinoma metastasis by stimulating mast cells to secrete exosomal shuttle microRNAs. Oncol. Lett. 14, 2141–2146.

91. Ono, M., Kosaka, N., Tominaga, N., YoshioKa, Y., Takeda, F., Takahashi, R.U., Yoshida, M., Tsuda, H., Tamura, K., and Ochiya, T. (2014). Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci. Signal. 7, ra63.

92. Kobayashi, M., Salomon, C., Tapia, J., Illanes, S.E., Mitchell, M.D., and Rice, G.E. (2014). Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. J. Transl. Med. 12, 4.

93. Camacho, L., Guerero, P., and Marchetti, D. (2013). MicroRNA and protein profiling of brain metastasis competent cell-derived exosomes. PLoS ONE 8, e73790.
113. Wei, Y., Lai, X., Yu, S., Chen, S., Ma, Y., Zhang, Y., Li, H., Zhuo, X., Yao, L., and Zhang, J. (2014). Exosomal miR-21/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res. Treat. 147, 423–431.

114. Yuwen, D.L., Sheng, B.B., Liu, J., Wenyu, W., and Shu, Y.Q. (2017). MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer. Eur. Rev. Med. Pharmacol. Sci. 21, 2650–2658.

115. Qin, X., Yu, S., Zhou, L., Shi, M., Hu, Y., Xu, X., Shen, B., Liu, S., Yan, D., and Feng, J. (2017). Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner. Int. J. Nanomedicine 12, 3721–3733.

116. Zheng, P., Chen, L., Yuan, Y., Luo, S., Li, Y., Xie, G., Ma, Y., and Shen, L. (2017). Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J. Exp. Clin. Cancer Res. 36, 53.

117. Yan, W., Wu, X., Zhou, W., Fong, M.Y., Cao, M., Liu, J., Liu, X., Chen, C.H., Fadare, O., Pizzo, D.P., et al. (2018). Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat. Cell Biol. 20, 597–609.

118. Shu, S.L., Yang, Y., Allen, C.L., Maguire, O., Minderman, H., Sen, A., Ciesielski, M.J., Dai, G., Yao, X., Zhang, Y., Gu, J., Geng, Y., Xue, F., and Zhang, J. (2018). Colorectal ARHGAP1 and FAM134A. Proc. Natl. Acad. Sci. USA 115, 2943–2948.

119. Fang, T., Lv, H., Li, T., Wang, C., Han, Q., Yu, L., Su, B., Guo, L., Huang, S., et al. (2018). Tumor-derived exosomal miR-1247-3p induces cancer-associated invasion and cancer metastasis. J. Cell. Physiol.

120. Dai, G., Yao, X., Zhang, Y., Gu, J., Geng, Y., Xue, F., and Zhang, J. (2018). Colorectal cancer cell-derived exosomes containing miR-10b regulate fibroblast activation to foster lung metastasis of liver cancer. Nat. Commun. 9, 191.

121. Donnarumma, E., Fiore, D., Nappa, M., Rossicchio, G., Adamo, A., Iaboni, M., Russo, V., Affinito, A., Pusti, I., Quintavalle, C., et al. (2017). Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer. Oncotarget 8, 19592–19603.

122. Bhome, R., Goh, R.W., Bullock, M.D., Pillar, N., Thirdborough, S.M., Mellone, M., Mirnezami, R., Galea, D., Veselkov, K., Gu, Q., et al. (2017). Exosomal microRNAs derived from colorectal cancer-associated fibroblasts: role in driving cancer progression. Aging (Albany NY.) 9, 2666–2694.

123. Az Yeung, C.L., Co, N.N., Tsuruga, T., Yeung, T.L., Kwan, S.Y., Leung, C.S., Li, Y., Ren, B., and Jin, P. (2018). Exosomal miR-6803-5p as potential diagnostic and prognostic biomarker for human esophageal squamous cell carcinoma. J. Cancer 9, 1159–1167.

124. Takeshita, N., Hoshino, I., Mori, M., Akutsu, Y., Hanari, N., Yoneyama, I., Ikeda, N., Isozaki, Y., Maruyama, T., Akamura, N., et al. (2013). Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br. J. Cancer 108, 644–652.

125. Shi, R., Wang, P.Y., Li, X.Y., Chen, J.X., Li, Y., Zhang, K.Z., Zhang, G.C., Jiang, T., Li, W.B., Ding, W., and Cheng, S.J. (2015). Exosomal levels of miR-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. Oncotarget 6, 26971–26981.

126. Fu, F., Jiang, W., Zhou, L., and Chen, Z. (2018). Circulating Exosomal miR-17-5p and miR-92a-3p Predict Pathologic Stage and Grade of Colorectal Cancer. Transl. Oncol. 11, 221–232.

127. Yan, S., Jiang, Y., Liang, C., Cheng, M., Jin, C., Duan, Q., Xu, D., Yang, L., Zhang, X., Ren, B., and Jin, P. (2018). Exosomal miR-6803-5p as potential diagnostic and prognostic marker in colorectal cancer. J. Cell. Biochem. 119, 4113–4119.

128. Peng, Z.Y., Gu, R.H., and Yan, B. (2019). Downregulation of exosome-encapsulated miR-548c-5p is associated with poor prognosis in colorectal cancer. J. Cell. Biochem. 120, 1457–1463.

129. Lan, F., Qing, Q., Pan, Q., Hu, M., Yu, H., and Yue, X. (2018). Serum exosomal miR-30a as a potential diagnostic and prognostic biomarker for human glioma. Cell Oncol. (Dordr.) 41, 25–33.

130. Yoshikawa, M., Inuma, H., Umeno, Y., Yanagisawa, T., Matsumoto, A., and Jinno, H. (2018). Exosome-encapsulated microRNA-223-3p as a minimally invasive biomarker for the early detection of invasive breast cancer. Oncol. Lett. 15, 9584–9592.

131. Zhang, W., Ni, M., Su, Y., Wang, H., Zhu, S., Zhao, A., and Li, G. (2018). MicroRNAs in Serum Exosomes as Potential Biomarkers in Clear-cell Renal Cell Carcinoma. Eur. Urol. Focus 4, 412–419.

132. Meng, X., Müller, V., Miöle-Langosch, K., Trissl, F., Pantel, K., and Schwarzenbach, H. (2016). Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-20a, miR-20b and miR-20c in patients with epithelial ovarian cancer. Oncotarget 7, 16923–16935.

133. Shi, M., Jiang, Y., Yang, L., Yan, S., Wang, Y.G., and Lu, X.J. (2018). Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular carcinoma. J. Cell. Biochem. 119, 4711–4716.
148. Liu, C., Eng, C., Shen, J., Lu, Y., Takata, Y., Mehdizadeh, A., Chang, G.I., Rodriguez-Bigas, M.A., Li, Y., Chang, P., et al. (2016). Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer. Oncotarget 7, 76250–76260.

149. Manier, S., Liu, C.J., Avet-Loiseau, H., Park, J., Shi, J., Campigotto, F., Salem, K.Z., Huynh, D., Glavey, S.V., Rivotto, B., et al. (2017). Prognostic role of circulating -exo-somal miRNAs in multiple myeloma. Blood 129, 2429–2436.

150. Du, M., Giridhar, K.V., Tian, Y., Tschannen, M.R., Zhu, J., Huang, C.C., Kilari, D., Kohli, M., and Wang, L. (2017). Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer. Oncotarget 8, 63703–63714.

151. Li, L., Sun, Y., Feng, M., Wang, L., and Liu, J. (2018). Clinical significance of blood-based miRNAs as biomarkers of non-small cell lung cancer. Oncol. Lett. 15, 8915–8925.

152. Lu, C.Y., Chen, S.Y., Peng, H.L., Kan, P.Y., Chang, W.C., and Yen, C.J. (2017). Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma. Oncotarget 8, 6406–6418.

153. Chalmin, F., Ladoire, S., Mignot, G., Vincent, J., Bruchard, M., Remy-Martin, J.P., Boireau, W., Rouleau, A., Simon, B., Lanneau, D., et al. (2010). Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 120, 457–471.

154. Al-Nedawi, K., Meehan, B., Kerbel, R.S., Allison, A.C., and Rak, I. (2009). Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc. Natl. Acad. Sci. USA 106, 3794–3799.

155. Liao, Y., Yin, X., Deng, Y., and Peng, X. (2018). MiR-140-5p suppresses retinoblastoma cell growth via inhibiting c-Met/AKT/mTOR pathway. Biosci. Rep. 38, BSR20180776.

156. Wang, Y.F., Yang, H.Y., Shi, X.Q., and Wang, Y. (2018). Upregulation of microRNA-129-5p inhibits cell invasion, migration and tumor angiogenesis by inhibiting ZIC2 via downregulation of the Hedgehog signaling pathway in cervical cancer. Cancer Biol. Ther. 19, 1162–1173.

157. Wang, W.T., Qi, Q., Zhao, P., Li, C.Y., Yin, X.Y., and Yan, R.B. (2018). miR-590-3p is a novel microRNA which suppresses osteosarcoma progression by targeting SOX9. Biomed. Pharmacother. 107, 1763–1769.

158. Mitchell, P.S., Parkin, R.K., Kroh, E.M., Fritz, B.R., Wyman, S.K., Pogosova-Agadjanyan, E.L., Peterson, A., Noteboom, J., O’Brian, K.C., Allen, A., et al. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 105, 10513–10518.

159. Li, Y., Shen, Z., and Yu, X.Y. (2015). Transport of microRNAs via exosomes. Nat. Rev. Cardiol. 12, 198.

160. Sun, Z., Shi, K., Yang, S., Liu, J., Zhou, Q., Wang, G., Song, J., Li, Z., Zhang, Z., and Yuan, W. (2018). Effect of exosomal miRNA on cancer biology and clinical applications. Mol. Cancer 17, 147.

161. Kahroba, H., Hejazi, M.S., and Samadi, N. (2019). Exosomes: from carcinogenesis and metastasis to diagnosis and treatment of gastric cancer. Cell. Mol. Life Sci. 76, 1747–1758.

162. Christianson, H.C., Svensson, K.J., van Kuppevelt, T.H., Li, J.P., and Belting, M. (2013). Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. Proc. Natl. Acad. Sci. USA 110, 17380–17385.

163. Shimbo, K., Miyaki, S., Ishitobi, H., Kato, Y., Kubo, T., Shimose, S., and Ochi, M. (2014). Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration. Biochem. Biophys. Res. Commun. 445, 381–387.

164. Yu, D.D., Wu, Y., Shen, H.Y., Lv, M.M., Chen, W.X., Zhang, X.H., Zhong, S.L., Tang, J.H., and Zhao, J.H. (2015). Exosomes in development, metastasis and drug resistance of breast cancer. Cancer Sci. 106, 959–964.

165. Zhou, Y., Zhou, G., Tian, C., Jiang, W., Jin, L., Zhang, C., and Chen, X. (2016). Exosome-mediated small RNA delivery for gene therapy. Wiley Interdiscip. Rev. RNA 7, 758–771.